## 6.C Board practices

# **Corporate governance** Framework

Novartis is committed to effective corporate governance, and our corporate governance framework is intended to support sustainable financial performance and longterm value creation for our shareholders, patients, employees and other stakeholders based on our Values and Behaviors.

Novartis AG is subject to and compliant with the laws and regulations of Switzerland (in particular Swiss company and securities law, SIX Swiss Exchange rules and the Swiss Code of Best Practice for Corporate Governance) and the securities laws of the United States, including New York Stock Exchange (NYSE) listing standards applicable to foreign private issuers of securities.

The Novartis corporate governance principles are described in key governance documents, in particular in our Articles of Incorporation and the Organizational Regulations of Novartis AG ("Board Regulations") (www. novartis.com/investors/company-overview/corporate-governance).

The Governance, Sustainability and Nomination Committee (GSNC) regularly reviews both the corporate governance principles and the key governance documents against evolving best practice standards and new developments in line with our commitment to maintaining the highest standards.

### **Governance bodies**

#### **GENERAL MEETING OF SHAREHOLDERS**

Approves operating and financial review, Novartis Group consolidated financial statements, and financial statements of Novartis AG: decides appropriation of available earnings and dividend: approves compensation of Board and Executive Committee; elects Board members, Board Chair, Compensation Committee members, Independent Proxy and external auditor; adopts and modifies Articles of Incorporation

#### **BOARD OF DIRECTORS**

AUDIT AND COMPLIANCE COMMITTEE

COMPENSATION GOVERNANCE, COMMITTEE SUSTAINABILITY COMMITTEE

Sets strategic direction of Novartis, appoints and oversees key executives, approves major transactions

RISK AND NOMINATION

**SCIENCE &** COMMITTEE TECHNOLOGY COMMITTEE

**EXTERNAL AUDITOR** 

Provides opinion on compliance of Novartis Group consolidated financial statements and the financial statements of Novartis AG with applicable standards and Swiss law, on compliance of the Compensation Report with applicable law and on effectiveness of internal controls over financial reporting.

**EXECUTIVE COMMITTEE** 

Responsible for operational management of Novartis

and investments, adopts and modifies Board Regulations

## Group structure and shareholders

## **Group structure**

#### **Novartis AG and Group companies**

Novartis AG, the Group's holding company, is a corporation organized under Swiss law with issued registered shares and registered office at Lichtstrasse 35, CH-4056 Basel, Switzerland.

The principal subsidiaries and associated companies of the Novartis Group are shown in "Item 18. Financial Statements—Note 31. Novartis principal subsidiaries and associated companies."

#### **Organizational structure**

Novartis is an innovative medicines company. Its five organizational units represent parts of the Company along the research and development/production/commercialization continuum. These are Biomedical Research, Development, Operations and the two commercial units – US and International – which focus on their respective geographic areas.



## **Shareholdings**

#### Listed companies belonging to the Novartis Group

Novartis owns 70.68% of Novartis India Ltd., with its registered office in Mumbai, India, and a listing on the BSE (formerly known as the Bombay Stock Exchange) (ISIN INE234A01025, symbol: HCBA). The total market value of the 29.32% free float of Novartis India Ltd. was USD 77.7 million on December 31, 2024, using the quoted market share price at year-end. Applying this share price to all shares of Novartis India Ltd, the market capitalization of the whole company was USD 265.0 million, and that of the shares owned by Novartis was USD 187.3 million.

## Shareholders

#### Significant shareholders

According to the Share Register, as of December 31, 2024, the following registered shareholders, including nominees and the American Depositary Share (ADS) depositary, held more than 2% of the total share capital, with the right to vote all their shares based on exemptions granted by the Board (see "—Item 6.C Board practices—Shareholder participation—Voting rights, restrictions and representation—Registration restrictions"):\*

	% holding of share capital Dec 31, 2024
Shareholders registered for their own account:	
UBS Fund Management (Switzerland) AG, Basel	5.3
Emasan AG, Basel <sup>1</sup>	4.1
Credit Suisse Funds AG, Zurich <sup>2</sup>	

<sup>1</sup> According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, the beneficial owner of the shares registered for Emasan AG is Sandoz – Fondation de Famille, Liechtenstein.

 $^{\rm 2}$  Credit Suisse Funds AG merged into UBS Fund Management (Switzerland) AG on April 30, 2024.

	% holding of share capital Dec 31, 2024
Shareholders registered as nominees:	
Nortrust Nominees Ltd., London	3.5
The Bank of New York Mellon, New York	2.8
Through The Bank of New York Mellon, Everett	1.3
Through The Bank of New York Mellon, New York	1.0
Through The Bank of New York Mellon, SA/NV, Brussels	0.5
Shareholder acting as American Depositary Share (ADS	6) depositary:
JPMorgan Chase Bank, N.A., New York	8.0

According to a disclosure notification filed with Novartis AG, Norges Bank (Central Bank of Norway), Oslo, held 2.3% of the share capital but was not registered in the Share Register as of December 31, 2024.

According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, BlackRock, Inc., New York, held between 5% and 10% but was registered with less than 2% of the share capital as of December 31, 2024.

Disclosure notifications pertaining to shareholdings filed with Novartis AG and the SIX Swiss Exchange are published on the latter's electronic publication platform: www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html.

9.7% of the share capital is held as treasury shares by Novartis AG or its fully owned subsidiaries (including Swiss foundations controlled by Novartis AG). Percentages in the two tables below are calculated on the basis of 2 189 930 497 ordinary shares including such treasury shares.

#### Duty to make an offer

According to the Swiss Federal Act on Financial Infrastructures, anyone who – directly, indirectly or acting in concert with third parties – acquires equity securities exceeding 33.3% of the voting rights of a company (whether or not such rights are exercisable) is required to make an offer to acquire all listed equity securities of that company. A company may raise this threshold up to 49% of the voting rights ("opting up") or may, under certain circumstances, waive the threshold ("opting out"). Novartis AG has not adopted any such measures.

#### **Cross shareholdings**

Novartis AG has no cross shareholdings in excess of 5% of capital, or voting rights with any other company.

#### **Overview on shareholder structure**

The following tables relate only to registered shareholders and cannot be assumed to represent the entire investor base because nominees and JPMorgan Chase Bank, N.A., as ADS depositary, are registered as shareholders for a large number of beneficial owners.

As of December 31, 2024, Novartis AG had approximately 186 000 registered shareholders.

#### Number of registered shareholders/shares

As of December 31, 2024 <sup>1</sup>	Number of registered shareholders	% of share capital
1–100	39 042	0.10
101–1 000	108 290	1.97
1 001–10 000	35 269	4.41
10 001–100 000	2 986	3.42
100 001–1 000 000	428	5.90
1 000 001–5 000 000	57	5.54
5 000 001 or more	24	34.14
Total registered shareholders/shares <sup>2</sup>	186 096	55.48
Unregistered shares		44.52
Total		100.00

<sup>1</sup> At the record date of the 2024 Annual General Meeting of Shareholders (AGM), unregistered shares amounted to 22.8%.

<sup>2</sup> Including 9.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries (including Swiss foundations controlled by Novartis AG).

#### **Registered shareholders by type**

As of December 31, 2024	Shareholders in %	Shares in %
Individual shareholders	96.94	20.47
Legal entities <sup>1</sup>	3.03	45.14
Nominees, fiduciaries and ADS depositary	0.03	34.39
Total	100.00	100.00

<sup>1</sup> Excluding 9.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries (including Swiss foundations controlled by Novartis AG).

#### Registered shareholders by country<sup>1</sup>

As of December 31, 2024	Shareholders in %	Shares in %
Belgium	0.10	1.04
Canada	0.03	0.57
France	2.11	0.51
Germany	5.94	2.12
Ireland	0.58	0.65
Luxembourg	0.06	1.00
Sweden	0.08	0.57
Switzerland <sup>2</sup>	84.80	56.50
United Kingdom	0.70	10.89
United States	0.22	23.85
Other countries	5.38	2.30
Total	100.00	100.00

1 Registered shares held by nominees are shown in the country where the company/

affiliate entered in the Share Register as shareholder has its registered office.

<sup>2</sup> Excluding 9.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries (including Swiss foundations controlled by Novartis AG).

## **Capital structure**

## **Share capital**

As of December 31, 2024, the share capital amounted to CHF 1 073 065 943.53 fully paid-in and divided into 2 189 930 497 registered shares with a nominal value of CHF 0.49 each.

Shares are listed on the SIX Swiss Exchange (ISIN CH0012005267, symbol: NOVN) and on the New York Stock Exchange (NYSE) in the form of American Depositary Receipts (ADRs) representing American Depositary Shares (ADSs) (ISIN US66987V1098, symbol: NVS).

No conditional capital exists as of December 31, 2024 nor has a capital band been introduced in the Company's Articles of Incorporation.

## Shares, participation certificates, non-voting equity securities, profitsharing certificates

Shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.

#### Average repurchase AGM Shareholder decision Shares canceled share price (CHF) 2022 • Capital reduction by CHF 15.35 million (from CHF 1 217 210 460.00 to CHF 1 201 860 626.00) 30 699 668 81.82 Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion between the 2022 AGM and the 2025 AGM 2023 • Capital reduction by CHF 63.12 million (from CHF 1 201 860 626.00 to CHF 1 138 738 876.00) 126 243 500 81.56 Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion between the 2023 AGM and the 2026 AGM <sup>3</sup> 2024 • Capital reduction by CHF 42.90 million (from CHF 1 115 964 098.48 to CHF 1 073 065 943.53) 87 547 255 86.36 EGM Shareholder decision 2023 • Capital reduction by CHF 22.77 million (from CHF 1 138 738 876.00 to CHF 1 115 964 098.48) by reducing the par value of each share from CHF 0.50 to CHF 0.49 Average repurchase AGM Proposal to the shareholders Shares to be canceled share price (CHF) • Capital reduction by CHF 37.98 million (from CHF 1 073 065 943.53 to CHF 1 035 086 714.83) 2025 77 508 630 94.23

### **Changes to share capital**

<sup>1</sup> All shares were repurchased on the SIX Swiss Exchange second trading line

Authorization of the Board to repurchase shares up to CHF 10 billion between

<sup>2</sup> In addition to the remaining authorization from the 2021 AGM

the 2025 AGM and the 2028 AGM 4

 $^{\scriptscriptstyle 3}$  In addition to the remaining authorization from the 2022 AGM

<sup>4</sup> In addition to the remaining authorization from the 2023 AGM

## **Convertible securities and options**

Novartis AG has not issued convertible or exchangeable bonds, warrants, options or other securities granting rights to shares, other than certain instruments granted under or in connection with equity-based participation plans of employees.

## Limitation on transferability

No transferability restrictions are imposed on shares (for registration restrictions, see "—Item 6.C Board practices— Shareholder participation—Voting rights, restrictions and representation—Registration restrictions"). The registration of shareholders in the Share Register or in the ADR register kept by JPMorgan Chase Bank, N.A., does not affect the tradability of shares or ADRs.

### Key Novartis share data

	2024	2023	2022
Issued shares	2 189 930 497	2 277 477 752	2 403 721 252
Treasury shares <sup>1</sup>	214 841 249	233 443 766	284 112 195
Outstanding shares at December 31	1 975 089 248	2 044 033 986	2 119 609 057
Weighted average number of shares outstanding	2 018 281 520	2 076 794 140	2 181 180 341

<sup>1</sup> Approximately 86 million treasury shares (2023: 94 million 2022: 99 million) are held in Novartis entities that restrict their availability for use.

### **Per-share information**<sup>1</sup>

	2024	2023	2022
Basic earnings per share from continuing operations (USD)	5.92	4.13	2.77
Diluted earnings per share from continuing operations (USD)	5.87	4.10	2.76
Net cash flows from operating activities from continuing operations (USD)	8.73	6.85	5.98
Year-end equity for Novartis AG shareholders (USD)	22.30	22.83	28.00
Dividend (CHF) <sup>2</sup>	3.50	3.30	3.20
Dividend (USD) <sup>3</sup>	3.87	3.76	3.51

<sup>1</sup> Calculated on the weighted average number of shares outstanding, except year-end equity.

<sup>2</sup> 2024: proposal to shareholders for approval at the AGM on March 7, 2025.

<sup>3</sup> Translated into US dollars at the December 31, 2024, rate of USD 1.107 to the Swiss franc. This translation is an example only, and should not be construed as a representation that the Swiss franc amount represents, or has been or could be converted into US dollars at that or any other rate. 2023 and 2022, dividends are translated into US dollars at the Bloomberg Market System Rate on the payment date.

### **Key ratios – December 31**

	2024	2023	2022
Price/earnings ratio <sup>1</sup>	16.6	14.1	28.3
Dividend yield (%) <sup>1</sup>	3.9	3.9	3.8

<sup>1</sup> Based on the Novartis share price at December 31 of each year

### Key data on ADRs issued in the US

	2024	2023	2022
Year-end ADR price (USD)	97.31	100.97	90.72
High <sup>1</sup>	120.89	105.13	93.75
Low <sup>1</sup>	92.57	80.03	74.61
Number of ADRs outstanding <sup>2</sup>	174 267 912	189 633 312	225 435 680

<sup>1</sup> Based on daily closing prices

<sup>2</sup> The depositary, JPMorgan Chase Bank, N.A., holds one Novartis AG share for every ADR issued.

## Share price (CHF)

	2024	2023	2022
Year-end share price	88.70	84.87	83.59
High <sup>1</sup>	102.70	93.87	87.82
Low <sup>1</sup>	84.52	74.62	73.98
Year-end market capitalization (USD billions) <sup>2</sup>	193.9	206.3	191.5
Year-end market capitalization (CHF billions) <sup>2</sup>	175.2	173.5	177.2

<sup>1</sup> Based on daily closing prices

<sup>2</sup> Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the year-end CHF/USD exchange rate.

## **Shareholder participation**

## Shareholder engagement

Shareholder engagement is fundamental to our commitment to governance and transparency, and the feedback we receive during these engagements helps us create long-term and sustainable value.

We concentrate our outreach efforts on our largest 100 shareholders – portfolio managers, buy-side professionals, stewardship teams and ESG analysts – who represent approximately 60% of our ownership. While the Board Chair, CEO and CFO, together with Investor Relations, are accountable for ensuring effective shareholder engagement, other senior managers from within and outside the Executive Committee also participate in the meetings. We conduct regular outreach to investors throughout the year.

#### **TYPES OF ENGAGEMENTS (SELECT EXAMPLES):**

- · AGM and quarterly results webcasts
- · Bank conferences and management roadshows
- "Meet Novartis Management" capital markets event
- Pipeline updates i.e. ASCO investor event, Renal Portfolio Update webcast
- · Governance roadshow and teleconferences
- · Board Chair's meetings with Swiss, US and UK investors
- · Annual ESG investor event, captioned "Impact and Sustainability"

#### **TOPICS DISCUSSED WITH SHAREHOLDERS DURING 2024:**

#### ACCELERATE GROWTH AND RETURNS:

- Growth drivers (including *Entresto*, *Cosentyx*, *Kesimpta*, *Kisqali* and *Pluvicto*)
- Replacement power
- · Innovation milestones (i.e. Scemblix, Fabhalta, Kisqali)
- Policy and pricing environment

#### DELIVER THROUGH OPERATIONAL EXCELLENCE:

- · Progress on financial, strategic and operational performance
- Return on R&D investments
- · Capital allocation strategy
- · New organizational model

#### STRENGTHEN FOUNDATIONS:

- · Strong governance and focus on key ESG factors
- · Enabling access to medicines with the Novartis Access Principles
- Progress on ESG targets: including carbon, water, waste, gender balance in management

#### **COMPENSATION AND GOVERNANCE:**

- · Diversity of the Board, the Executive Committee, and the Company
- · Board renewal, succession planning and evaluation
- The linking of the compensation system to performance and strategic priorities

## Voting rights, restrictions and representation

#### REGISTRATION

Shareholders have the right to vote and to execute all other rights as granted under Swiss law and the Articles of Incorporation (see, in particular, articles 17 and 18 of the Articles of Incorporation).

Each share registered with the right to vote by the third business day before the General Meeting entitles the holder to one vote at General Meetings. Article 5, paragraph 2 of the Articles of Incorporation provides that to be registered with voting rights, shareholders must declare that they acquired the shares in their own name and for their own account. According to article 5, paragraph 3 of the Articles of Incorporation, the Board may register nominees with the right to vote. The Share Register is a non-public register subject to statutory confidentiality and data privacy.

The Articles of Incorporation are available at www. novartis.com/investors/company-overview/corporate-governance.

#### **REGISTRATION RESTRICTIONS**

Article 5, paragraph 2 of the Articles of Incorporation provides that no shareholder shall be registered with the right to vote for more than 2% of the share capital. Given that shareholder representation at General Meetings has traditionally been comparatively low in Switzerland, Novartis AG considers registration restrictions necessary to prevent a minority shareholder from dominating a General Meeting. The Board may, upon request, grant an exemption. Considerations include if the shareholder supports our goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered shareholders listed in "-Item 6.C Board practices-Group structure and shareholders-Shareholders-Significant shareholders." An exemption also applies to Norges Bank (Central Bank of Norway), Oslo, which as of December 31, 2024, was not registered but held 2.3% according to a disclosure notification filed with Novartis AG. No further exemptions were requested in 2024. The same restrictions indirectly apply to ADR holders.

Article 5, paragraph 3 of the Articles of Incorporation provides that no nominee shall be registered with the right to vote for more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. Exemptions are in force for the nominees listed in "—Item 6.C Board practices—Group structure and shareholders—Shareholders—Significant shareholders," and for the nominee Citibank, London, which in 2015 requested an exemption, but as of December 31, 2024, was not registered in the Share Register. The same restrictions indirectly apply to ADR holders. According to article 5, paragraph 4 of the Articles of Incorporation, shareholders, ADR holders, or nominees who are linked to each other or who act in concert to circumvent registration restrictions are treated as one person or nominee for the purposes of the restrictions on registration.

The registration restrictions may be changed by resolution of the General Meeting, with approval of at least two-thirds of the votes represented at the meeting.

The Articles of Incorporation are available at www. novartis.com/investors/company-overview/corporate-governance.

#### ATTENDANCE, REPRESENTATION AND WEB PORTAL

Registered shareholders will receive a personal invitation letter to the General Meetings with an access code to log in to our web portal, and – if the shareholder did not use the web portal in the past – a printed invitation brochure and a registration/proxy form. By returning the registration/proxy form or using the web portal, shareholders can order an admission ticket for the General Meeting or appoint a representative of their choice by means of a written proxy or the Independent Proxy to vote their shares on their behalf.

If the Independent Proxy is appointed, shareholders can also give voting instructions on agenda items or on alternative or additional motions related to the agenda items either (i) following the recommendations of the Board for such alternative or additional motions; or (ii) opposing such alternative or additional motions. They can also abstain from voting.

#### ADR HOLDERS

ADR holders have the rights enumerated in the deposit agreement (such as the right to give voting instructions and to receive dividends). The ADS depositary of Novartis AG – JPMorgan Chase Bank, N.A., New York – holds the shares underlying the ADRs and is registered as a shareholder in the Share Register. An ADR is not a share, and an ADR holder is not a Novartis AG shareholder. Each ADR represents one share. ADR holders exercise their voting rights by instructing the depositary to exercise their voting rights. The ADS depositary exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee must be a shareholder.

## **Annual General Meeting (AGM)**

#### CONVENING

The AGM must be held within six months of the end of our financial year (December 31), and normally takes place in late February or early March. According to article 12a of the Articles of Incorporation (www.novartis.com/investors/ company-overview/corporate-governance), the Board may foresee that shareholders who cannot be present at the venue of the AGM may exercise their rights through electronic means. The Board may at any time until June 30, 2028<sup>1</sup> also order that the AGM be held electronically without a venue. Extraordinary General Meetings may be requested by the Board, the external auditor, or shareholders representing at least 5% of the share capital.

#### AGENDA

Shareholders representing shares with an aggregate nominal value of at least CHF 1 million may request that an item be included in a General Meeting agenda. Such requests must be made in writing at least 45 days before the meeting, specifying the requested item and proposal. If an explanatory statement is to be included in the notice of meeting, it must be submitted within the same period, and formulated in a short, clear and concise manner.

#### POWERS

According to article 17 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following powers are vested exclusively in the General Meeting:

- · Adoption and amendment of the Articles of Incorporation
- Election and removal of the Board Chair, the Board and Compensation Committee members, the Independent Proxy and the external auditor
- Approval of the management report, the consolidated financial statements and the report on non-financial matters
- Approval of the financial statements of Novartis AG, and the decision on the appropriation of available earnings shown on the balance sheet, in particular with regard to dividends (including any repayment of the statutory capital reserves and the approval of interim dividends and the interim financial statements required for such purpose)
- Approval of the maximum aggregate compensation of the Board (from one AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM). If the maximum aggregate amount of compensation already approved by the AGM is not sufficient to cover the compensation of newly appointed or promoted Executive Committee members, Novartis may use up to 40% of the amount last approved for the newly appointed or promoted Executive Committee members
- Discharge of Board and Executive Committee members
- Delisting of the shares of Novartis AG
- Decisions on other matters that are reserved by law or by the Articles of Incorporation (e.g., advisory vote on the Compensation Report) to the General Meeting

<sup>1</sup> In accordance with the statement by the Board issued on February 10, 2023, Novartis commits to submitting the corresponding authorization again to a shareholder vote at the 2025 Annual General Meeting, regardless of the time limitation stipulated in the Articles of Incorporation.

#### STATUTORY QUORUMS

The General Meeting passes resolutions and elections with an absolute majority of the votes represented at the meeting. However, under article 18 of the Articles of Incorporation (www.novartis.com/investors/company-overview/ corporate-governance), the approval of two-thirds of the votes represented at the meeting is required for:

- · An alteration of the purpose of Novartis AG
- The consolidation of shares, unless the approval of all affected shareholders is required
- An increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights
- An increase of the share capital out of equity, by contributions in kind by way of set-off against a receivable and the grant of special rights
- A restriction or cancellation of rights of options to subscribe

- The introduction of a conditional capital or a capital band
- An implementation of restrictions on the transfer of registered shares, and the removal of such restrictions
- The creation of shares with increased voting powers
- The change of the currency of the share capital
- The introduction of the deciding vote for the presiding officer at the General Meeting of Shareholders
- A provision in the Articles of Incorporation allowing to hold the General Meeting of Shareholders abroad
- The delisting of the shares of Novartis AG
- A change of the registered office of Novartis AG
- The introduction of an arbitration clause in the Articles of Incorporation
- The merger, split or transformation of Novartis AG under the Merger Act (subject to mandatory provisions)
- The dissolution of Novartis AG

N. Andrews

T. Buechner

E. Doherty

B. Heller

## **Board of Directors**

### Composition (as per December 31, 2024)

**BOARD CHAIR:** J. Reinhardt

VICE-CHAIR: S. Moroney

AUDIT AND COMPLIANCE COMMITTEE	COMPENSATION COMMITTEE	GOVERNANCE, SUSTAINABILITY AND NOMINATION COMMITTEE	RISK COMMITTEE	SCIENCE & TECHNOLOGY COMMITTEE
E. Doherty (Chair) T. Buechner B. Heller D. Hochstrasser F. van Houten A. de Pro Gonzalo	S. Moroney (Chair) P. Bula B. Heller W. Winters	P. Bula (Chair) B. Heller D. Hochstrasser C. Sawyers W. Winters	T. Buechner (Chair) N. Andrews E. Doherty A. de Pro Gonzalo J. Young	J. Young (Chair) N. Andrews F. van Houten S. Moroney C. Sawyers

## **Election and term of office**

Board members (including the Board Chair) and Compensation Committee members are elected individually by shareholders at the General Meeting for a one-year term of office. The term of office expires at the end of the next AGM.

According to article 20, paragraph 3 of the Articles of Incorporation, a member shall not serve on the Board for more than 12 years. Under special circumstances and if deemed to be in the best interest of the Company, the Board may recommend exceptions to the shareholders (www.novartis.com/investors/company-overview/corporate-governance).

The term limit supports our commitment to renew the Board on an ongoing basis and follows international best practice.

## Succession planning

The GSNC prepares and reviews succession plans for the Board on an annual basis. These plans are discussed by the Board in private meetings. A search for a new Board member is launched - normally with the support of a professional executive search company - with individual selection criteria defined based on the evolving needs of the Company and a continuing focus on diversity, skills and experience. The set of competencies (further explained in "—Item 6.C Board practices—Board of Directors—Board skills") and a balance between continuity of experience and fresh perspectives are also important criteria for the GSNC when evaluating new candidates. Candidates are

interviewed by the Board Chair, members of the GSNC, other Board members, and members of the Executive Committee. The GSNC then makes a recommendation to the full Board, and the Board ultimately decides who should be proposed for election at the upcoming AGM.

C. Sawvers W. Winters

J. Young

## Independence

D. Hochstrasser

A. de Pro Gonzalo

E van Houten

All Board members - including the Board Chair - are non-executive and independent, pursuant to applicable corporate governance rules and Novartis independence criteria, which are outlined in Appendix II to the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In particular, no Board member is or was a member of the management of Novartis AG or of any other Novartis Group company in the last three financial years up to December 31, 2024, or has or had, a significant business relationship with Novartis AG or with any other Novartis Group company.

The independence of Board members is assessed annually. Each Board member completes an independence questionnaire that is reviewed by the GSNC. The GSNC then submits a proposal to the full Board, and the Board determines the independence status of each Board member.

The Board members are also subject to procedures to avoid conflicts of interest which are outlined in the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). Based on such procedures, Simon Moroney did not participate in any discussions regarding the acquisition of MorphoSys AG and did not have access to any underlying documents.


## **Diversity**

Novartis is dedicated to fostering an inclusive Board where individuals from all genders and ethnic backgrounds can thrive and contribute their unique insights. A diverse Board ensures that the appropriate balance of skills, expertise, experience, and cultural background is represented to discharge its responsibilities and to support long-term value creation for shareholders, patients, employees and other stakeholders.

Diversity remains a critical focus area for the Board, and the GSNC continuously examines opportunities to further increase the Board's diversity when identifying new Board member candidates. The GSNC considers gender, age, nationality, ethnicity and viewpoints, professional background, and expertise in its selection process.

Regarding gender diversity, the Board pledges to sustain its efforts to achieve 50% representation of both genders in the composition of the Board, within a range of +/-10%.

#### **Diversity profile**



<sup>1</sup> Please note that six Board members have dual nationalities. Each of these nationalities is counted as a half in the above chart.

## **Board skills**

Upon proposal by the GSNC, the Board has determined a diverse set of competencies for its members that aligns with our status as a listed company, as well as our business portfolio, geographic reach and culture. Within this set of competencies, Board members were asked to identify their most relevant skills based on their educational background, professional experience and personal achievements.

The GSNC assesses the set of competencies as well as the individual skills annually to ensure that an appropriate balance of skills, expertise, experience and diversity is represented on the Board.

To learn more about our Board members and their individual skills, see "—Item 6.C Board practices—Board of Directors—Members of the Board of Directors."

#### **Board skill distribution**

Medicine/healthcare/R&D	54% 7/13
Environmental, social and governance (ESG)	31% 4/13
Data/digital	23% 3/13
Leadership/management	85% 11/13
Finance/accounting	54% 7/13
Law/regulatory/risk management	69% 9/13

### **Members of the Board of Directors**



#### Joerg Reinhardt, Ph.D.

Chair since 2013 | Nationality: German | Year of birth: 1956

Joerg Reinhardt is a healthcare industry veteran whose career spans nearly 40 years. After receiving his doctorate in pharmaceutical sciences, Mr. Reinhardt joined Sandoz Pharma Ltd., a predecessor to Novartis, in 1982. He held a number of senior leadership positions at Novartis, including Chief Operating Officer and Head of the Vaccines and Diagnostics Division. Additionally, he led Bayer HealthCare AG as chair of the board of management and the executive committee from 2010 to 2013.

#### Professional experience

- Chair of the board of management and the executive committee. Baver HealthCare AG. Germany (2010-2013)
- Chief Operating Officer, Novartis AG, Switzerland (2008-2010)
- Head of the Vaccines and Diagnostics Division, Novartis AG, Switzerland (2006-2008)
- Various managerial positions at Sandoz Pharma Ltd. and Novartis AG, Switzerland (1982-2006)

#### Mandates Current:

- · Board member, Swiss Re AG, Switzerland
- Chair of the board of trustees, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland
- · Chair of the board of trustees, Novartis Foundation, Switzerland

#### Past:

Senate member, Helmholtz Association of German Research Centers, Germany (2021-2023)

#### Education

· Doctorate in pharmaceutical sciences, Saarland University, Germany

#### Key skills

- Medicine/healthcare/R&D & Environmental, social and governance (ESG)
   Leadership/management 

   Law/regulatory/risk management

#### Simon Moroney, D.Phil.

Board member since 2020 | Vice-Chair since 2022 | Nationality: German/New Zealander | Year of birth: 1959

As co-founder and CEO of MorphoSys AG, Simon Moroney played a central role in establishing the company as a force in the field of therapeutic antibodies, with one of the broadest pipelines of drug candidates in the industry. Mr. Moroney holds both a doctorate and a Master's degree in chemistry.

#### **Professional experience**

- Co-founder and CEO, MorphoSys AG, Germany (1992–2019)
- Research associate, Department of Pharmacology, University of Cambridge, UK (1991–1992)
- Assistant professor, Department of Chemistry, University of British Columbia, Canada (1989–1990)

#### Mandates

· Chair of the board of directors and the remuneration and nomination committee, Biotalys NV, Belgium

#### Education

- Doctorate in chemistry, University of Oxford, UK
- · Master's degree in chemistry, University of Waikato, New Zealand

#### Kev skills

Medicine/healthcare/R&D & Environmental, social and governance (ESG)

Leadership/management 
 Law/regulatory/risk management





#### Nancy C. Andrews, M.D., Ph.D.

Board member since 2015 | Nationality: American/Swiss | Year of birth: 1958

Nancy C. Andrews has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke University School of Medicine. Since 2023, Dr. Andrews is credited with conducting research that led to advances in understanding iron biology and iron diseases

#### Professional experience

- Professor in residence of pediatrics, Harvard Medical School, US (2023-present)
- Executive vice president and chief scientific officer, Boston Children's Hospital, US (2021-present) • Dean emerita, Duke University School of Medicine, and vice chancellor emerita for academic affairs,
  - Duke University, US (2017-present)
- Dean, Duke University School of Medicine, and vice chancellor for academic affairs, Duke University, US (2007-2017)
- Professor of pediatrics, pharmacology and cancer biology, Duke University, US (2007–2021)
  Dean for basic sciences and graduate studies, Harvard Medical School, US (2003–2007)
- Director, Harvard/MIT M.D.-Ph.D. Program, US (1999-2003)
- Biomedical research investigator, Howard Hughes Medical Institute, US (1993-2006)

#### Mandates Current:

- · Board member and chair of the science and technology committee, Charles River Laboratories International Inc., US
- · Board member, Maze Therapeutics Inc., US
- · Home secretary (since July 2023) and council member, National Academy of Sciences, US

#### Past:

- Chair, American Academy of Arts and Sciences, US (2017 2023)
- Member of the executive committee of the corporation, Massachusetts Institute of Technology, US (2019 - 2022)
- Council member, National Academy of Medicine, US (2013–2019)
- Member of the scientific management review board, National Institutes of Health, US (2014–2019)
- · Chair, Burroughs Wellcome Fund, US (2011-2019)

#### Education

- Doctor of medicine, Harvard Medical School, US
- Doctorate in biology, Massachusetts Institute of Technology, US
- · Master's and bachelor's degrees in molecular biophysics and biochemistry, Yale University, US

#### Key skills

Medicine/healthcare/R&D 

Leadership/management

#### Ton Buechner

Board member since 2016 | Nationality: Dutch/Swiss | Year of birth: 1965

Ton Buechner is an engineer by training who started his career in the oil and gas construction industry. Before becoming the CEO of Sulzer AG, he held several divisional leadership roles at the company and worked in markets including Asia. Mr. Buechner most recently served as CEO and chair of the executive board of AkzoNobel NV, where he introduced industry-leading ESG policies

#### Professional experience

- CEO and chair of the executive board, AkzoNobel NV, Netherlands (2012–2017)
- · CEO, Sulzer AG, Switzerland (2007-2011)
- President, Sulzer Pumps, Switzerland (2003-2006)
- President, Sulzer Turbomachinery Services, Switzerland (2000–2002)
- Various managerial positions at Sulzer AG, China and Switzerland (1994-2000)

#### Mandates

#### Current:

- · Chair of the board of directors and the strategy and sustainability committee, Burckhardt Compression AG, Switzerland
- Chair of the board of directors and the sustainability committee, Swiss Prime Site AG, Switzerland
- Member of advisory committee to the Ministry of Economic Affairs and Climate Policy ("Adviescommissie Maatwerkafspraken Verduurzaming Industrie"), Netherlands

#### Past:

- · Member of the presidential and shareholder committees, Voith GmbH & Co. KGaA, Germany
- (2014 2020)Member of the supervisory board, Voith GmbH & Co. KGaA, Germany (2014–2018)

#### Education

- Master of business administration, IMD business school, Switzerland
- · Master's degree in civil engineering, Delft University of Technology, Netherlands

#### Key skills

- Finance/accounting I Law/regulatory/risk management





#### **Patrice Bula**

Board member since 2019 | Lead Independent Director since 2022 | Nationality: Swiss | Year of birth: 1956

Patrice Bula has 40 years of global management experience and is a leader in the consumer goods industry across established and emerging markets. He has served in various senior roles at Nestlé SA, including as general manager of its businesses in China, Germany and South Africa. Most recently, he successfully led the Nestlé Group's brand strategies, digital marketing transformation and Nespresso business.

#### **Professional experience**

- · Executive vice president and head of strategic business units, marketing, sales and Nespresso, Nestlé SA, Switzerland (2011-2021)
- Market head of the Greater China region, Nestlé SA, Switzerland (2007-2011)
- · Market head of Germany, Nestlé SA, Switzerland (2003-2007)
- Head of the confectionery and biscuits strategic business unit, Nestlé SA, Switzerland (2000-2003) Various managerial positions at Nestlé SA, Switzerland (1980–2000)
- Mandates
- Current: · Board member and vice chair, Schindler AG, Switzerland
- Board chair, European Pizza Group Topco Sarl, Luxembourg
- Board chair, Froneri Lux Topco Sarl, Luxembourg
  Board member and chair of the ESG committee, New Tiger LLC, US

#### Past:

- · Co-chair (2020-2021) and board member (2015-2021), Cereal Partners Worldwide SA, Switzerland (Nestlé representative)
- Board member, Froneri Lux Topco Sarl, Luxembourg (Nestlé representative) (2016–2020)
   Board member, Bobst Group SA, Switzerland (2017–2019)
- Chair, Blue Bottle Coffee Inc., US (Nestlé representative) (2017-2019)
- · Chair, Nestlé Nespresso SA, Switzerland (Nestlé representative) (2011-2019)
- Board member, Hsu Fu Chi Food Companies, China (Nestlé representative) (2011–2019) Education
- · Program for executive development, IMD business school, Switzerland
- · Master's degree in economic sciences, HEC Lausanne, Switzerland

#### Kev skills

🛭 Énvironmental, social and governance (ESG) 🐱 Data/digital 🖷 Leadership/management Finance/accounting



#### Elizabeth (Liz) Doherty

Board member since 2016 | Nationality: British/Irish | Year of birth: 1957 | Audit Committee Financial Expert

Elizabeth (Liz) Doherty is an expert in finance and accounting who has broad operational experience in international consumer and retail businesses. She began her career in internal audit at Unilever PLC and has held senior finance and accounting roles there and at other companies including Tesco PLC and Reckitt Benckiser Group PLC.

#### Professional experience

- CFO (interim), Cognita Schools Ltd., UK (2014–2015)
- CFO and board member, Reckitt Benckiser Group PLC, UK (2011–2013)
   CFO (interim), City Inn, UK (2010)
- CFO, Brambles Ltd., Australia (2007-2009)
- Group international finance director, Tesco PLC, UK (2001–2007)
- Various managerial positions at Unilever PLC, UK (1981-2001)

#### Mandates Current:

- · Board member and chair of the audit committee, Corbion NV, Netherlands
- · Member of the supervisory board and chair of the audit committee, Royal Philips NV, Netherlands
- · Member of the advisory committee, Freya Holdco S.à.r.l., Luxembourg

#### Past:

- Advisor, Affinity Petcare SA and GB Foods SA, Spain (2017–2023)
  Board member, Dunelm Group PLC, UK (2013–2019)
- · Board member, HM Courts & Tribunals Service, UK (2015-2019)
- · Board member, Ministry of Justice, UK (2015-2019)
- Board member, Delhaize Group, Belgium (2013-2016) · Board member, Nokia Corp., Finland (2013-2016)

#### Education

- Fellow, Chartered Institute of Management Accountants, UK
- · Bachelor's degree in liberal studies in science (physics), University of Manchester, UK

#### Key skills



#### **Bridgette Heller**

Board member since 2020 | Nationality: American | Year of birth: 1961

Bridgette Heller has proven experience in the standalone divisions of companies such as Johnson & Johnson, Merck & Co. Inc. and Danone SA, and has served on the audit committees of ADT Corp. and Tech Data Corp. During her career, she has overseen the performance of CFOs and made decisions on strategic R&D priorities. Ms. Heller is an advocate for diversity, equity and inclusion, and traveled globally to reinforce Danone's commitment to infant and maternal health, inclusive diversity, an equitable workforce for women, and sustainable communities. She is co-founder and CEO of the Shirley Proctor Puller Foundation, an education and youth empowerment nonprofit, and devotes much of her time to strengthening education and sustainability in an underserved community in the US.

#### **Professional experience**

- Co-founder and CEO, Shirley Proctor Puller Foundation, US (2019-present)
- EVP and president of specialized nutrition, Danone SA, Netherlands (2017–2019)
  EVP of early life nutrition, Danone SA, Netherlands (2016–2019)
  EVP and president of consumer care, Merck & Co. Inc., US (2010–2015)
  Global president of the baby global business unit, Johnson & Johnson, US (2007–2009)

- · President of the US baby, kids and wound care business and of global innovation development,
- Johnson & Johnson, US (2005-2007)
- Managing partner, Heller Associates: Ideas for Growth Inc., US (2004–2005)
- CEO, Chung's Gourmet Foods, US (2003–2004)
  Various managerial positions at Kraft Foods Inc., US (1985–2003)

#### Mandates

- Current:
- Board member, Aramark, US
- Board member, Dexcom Inc., US
  Board member, Integral Ad Science Inc., US
- Board member, Newman's Own Inc., US
- · Member of the advisory board, Kellogg School of Management at Northwestern University, US
  - · Member of the board of trustees, Northwestern University, US
  - Board member, Newman's Own Foundation, US
  - · Board member, Shirley Proctor Puller Foundation, US
  - Past:
  - Board member, Tech Data Corp., US (2016–2020)

  - Board member, ADT Corp., US (2012–2016)
    Board member, Girls Inc., US (2002–2014)
  - Education
  - Master's degree in marketing and management policy, Kellogg School of Management at Northwestern University, US
  - · Bachelor's degree in economics and computer studies, Northwestern University, US
  - Kev skills

Medicine/healthcare/R&D & Environmental, social and governance (ESG)

🗠 Data/digital 🖶 Leadership/management 🗠 Finance/accounting 🕤 Law/regulatory/risk management

#### **Daniel Hochstrasser**

Board member since 2022 | Nationality: Swiss | Year of birth: 1960

Daniel Hochstrasser is an independent dispute resolution specialist practicing in Zurich, Switzerland. He led Bär & Karrer, one of the leading Swiss law firms, from 2011 to 2021 as CEO/Senior Partner. In addition, he was the head of the firm's dispute resolution practice for 15 years. He frequently represented parties in complex disputes arising from matters such as M&A transactions, industrial and infrastructure projects, and license, distribution and development agreements, particularly in the pharmaceutical industry. He has published extensively on arbitration and litigation, and lectures at the University of Zurich and the University of St. Gallen in Switzerland.

#### Professional experience

- Attorney-at-law, Daniel Hochstrasser AG, Switzerland (since January 2023)
- Attorney-at-law and partner, Bär & Karrer AG, Switzerland (1993–December 2022)
- Senior partner and chair of the board of directors, Bär & Karrer AG, Switzerland (2011-2021)
- Lawyer, District Court of Affoltern, Court of Appeals/Court of Cassation of Zurich, Switzerland (1987–1992)
- In-house lawyer, Staubli SA, France (1986–1987)

#### Mandates Current:

- · Chair of the board of directors, Daniel Hochstrasser AG, Switzerland Board member, Finland Arbitration Institute, Finland
- · Vice president, ICC Court of Arbitration, France
- · Member of the Ethics Court, Zurich Bar Association, Switzerland

#### Past:

- Chair of the board of directors, Bär & Karrer AG, Switzerland (2011-2021)
- Member, ICC Court of Arbitration, France (2015-2021)
- Member of the Court, Swiss Arbitration Chambers, Switzerland (2004-2014)

#### Education

- · Master of laws (LL.M.), Cornell Law School, US
- Bar examination, Switzerland
- · Licentiatus iuris, University of Zurich, Switzerland

#### Key skills

Law/regulatory/risk management



#### **Frans van Houten**

Board member since 2017 | Nationality: Dutch | Year of birth: 1960

Frans van Houten is passionate about purpose-driven innovation, entrepreneurship and business transfor-mation to drive customer value and competitiveness. Under his leadership as CEO of Royal Philips, the company transformed into a leading health technology solutions company, leveraging data and informatics to improve healthcare provider results, and became a forerunner across ESG dimensions, having become carbon neutral in its operations since 2020 and recycling over 90% of its waste. Mr. van Houten was an initiator of the World Economic Forum Compact for Responsive and Responsible Leadership as well as founder and co-chair of the Platform to Accelerate the Circular Economy.

#### **Professional experience**

- · CEO and chair of the executive committee and the board of management, Royal Philips NV, Netherlands (2011 - 2022)
- Interim management, ING Group NV, Netherlands (2009–2010)
   CEO and chair of the management board, NXP Semiconductors NV (formerly Philips Semiconductors NV), Netherlands (2004-2009)
- · Various managerial positions at Royal Philips Electronics NV, Netherlands (1986-2004)

#### Mandates

- Current:
- · Board chair, Absci Corporation, US
- Board chair, Castor EDC, Netherlands
- · Board member, Affidea Group, Netherlands
- · Board chair, Synthesis Health Inc. US

#### Past:

- Member of the steering committee, European Round Table for Industry (ERT), Belgium (2014-2022)
- Vice chair and member of the supervisory board, Philips Lighting, Netherlands (2016-2017)

#### Education

- · Master's degree in economics and business management, Erasmus University Rotterdam, Netherlands
- · Bachelor's degree in economics, Erasmus University Rotterdam, Netherlands

#### Key skills

🛿 Medicine/healthcare/R&D 🐭 Environmental, social and governance (ESG) 🐱 Data/digital Ecadership/management 🗠 Finance/accounting 🗇 Law/regulatory/risk management

#### Ana de Pro Gonzalo

Board member since 2022 | Nationality: Spanish | Year of birth: 1967 | Audit Committee Financial Expert

Since starting her career at Arthur Andersen, Ana de Pro Gonzalo has worked across a variety of industries, ranging from construction and real estate to engineering and telecommunications. With deep expertise in finance, capital markets and technology, she has held executive positions at several multinational companies. Most recently, she spent 10 years as chief financial officer of Amadeus IT Group, a leading software provider for the global travel and tourism industry.

#### Professional experience

- Chief financial officer, Amadeus IT Group SA, Spain (2010-2020)
- · Corporate general manager, Sacyr Vallehermoso SA, Spain (2002-2010)
- Deputy general manager and finance director, Metrovacesa SA, Spain (1994-2002)
- Senior auditor, Arthur Andersen SA, Spain (1990–1994)

#### Mandates Current:


- Board member, Mobico Group PLC, UK
- · Member of the supervisory board and chair of the Audit Committee, STMicroelectronics NV, Netherlands
- Past:
- · Board member, Indra Sistemas SA, Spain (2020-2022)
- · Board member, Merlin Properties Socimi SA, Spain (2015-2017)

#### Education

- · General management program (PDG), IESE Business School, Spain
- · Bachelor's degree in business studies, Complutense University of Madrid, Spain

#### Kev skills

- 😵 Environmental, social and governance (ESG) 🐱 Data/digital 🖷 Leadership/management
- E Finance/accounting law/regulatory/risk management





#### Charles L. Sawyers, M.D.

Board member since 2013 | Nationality: American | Year of birth: 1959

Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr. Sawyers co-developed the Novartis cancer drug Gleevec/ Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award

#### **Professional experience**

- Chair of the human oncology and pathogenesis program, Memorial Sloan Kettering Cancer Center, US (2006-present)
- Professor of medicine (2008-present), and professor of cell and developmental biology (2011-present), Weill Cornell Graduate School of Medical Sciences, US
- Investigator, Howard Hughes Medical Institute, US (2002-2006 and 2008-present)
- Associate chief, division of hematology-oncology, University of California, Los Angeles, US (1996–2006) Mandates

#### Current:

- Member, National Academy of Medicine, US
- Member, National Academy of Sciences, US
- Investigator, Howard Hughes Medical Institute, US

- Member, National Cancer Advisory Board, US (2012-2020)
- President, American Association for Cancer Research, US (2013-2014)
- Education
- Doctor of medicine, Johns Hopkins University School of Medicine, US
- · Bachelor's degree, Princeton University, US

#### Key skills

Medicine/healthcare/R&D

### William T. Winters

Board member since 2013 | Nationality: British/American | Year of birth: 1961

William T. Winters has extensive leadership experience in the financial sector. He began his career at JPMorgan Chase & Co. in 1983 and has held management roles across several market areas and in corporate finance. Mr. Winters founded Renshaw Bay LLP, an alternative asset management firm, and now serves as CEO of Standard Chartered PLC, where he is leading a digital transformation of the global bank.

#### **Professional experience**

- CEO, Standard Chartered PLC, UK (2015-present)
  Chair and CEO, Renshaw Bay LLP, UK (2011-2015)
  Co-CEO of the investment bank, JPMorgan Chase & Co., UK (2004-2010)
  Various managerial positions at JPMorgan Chase & Co., UK and US (1983-2004)

#### Mandates

Current: · Board member, Standard Chartered Bank PLC, UK

#### Past:

· Commissioner, Independent Commission on Banking, UK (2010-2011)

#### Education

- Master of business administration, Wharton School of the University of Pennsylvania, US
- · Bachelor's degree in international relations, Colgate University, US

#### Kev skills

Environmental, social and governance (ESG) 🗠 Data/digital 🐵 Leadership/management E Finance/accounting law/regulatory/risk management





#### John D. Young

Board member since March 2023 | Nationality: British/American | Year of birth: 1964

A scientist by training, John D. Young has over 35 years of experience in the healthcare industry and brings a wealth of experience in leadership, strategy, business development and commercialization of innovative medicines to the Novartis Board of Directors. He joined Pfizer in 1987 as a sales representative and held positions of increasing seniority across the company, including as a member of Pfizer's executive leadership team for a decade. As Pfizer's group president and chief business officer from 2019 until 2022, Mr. Young also played an integral role in the development and delivery of the Pfizer-BioNTech COVID-19 vaccine.

#### Professional experience

- Senior advisor to the CEO, Pfizer, US (2022)
- Group president and chief business officer, Pfizer, US (2019-2022)
- Group president, innovative health business, Pfizer, US (2018)
- Group president, essential health business, Pfizer, US (2014-2017)
- President and general manager, global primary care business unit, Pfizer, US (2012-2013) Regional president, primary care business unit for Europe and Canada, Pfizer, UK (2009-2012)
  Various managerial positions, Pfizer, UK and Australia (1987–2008)
- Mandates

#### Current:

- Board member and chair of the compensation committee, Arvinas Inc, US
  Board member, Johnson Controls International, Ireland
- Past:
- · Board member, Imbria Pharmaceuticals, US (2022-2024)
- Board member, Haleon, UK (2022-February 2023)
  Board member, GSK Consumer Health Joint Venture, UK (2019-2022)
- Board member, Biotechnology Innovation Organization (BIO), US (2018-2021)
- US bio-pharmaceutical representative, UK Government Life Sciences Council, UK (2007-2021)
- · Board member, National Committee for US China Relations, US (2014-2017)
- · Board member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium (2012 - 2017)

#### Education

- Master of business administration, University of Strathclyde, UK
- · Bachelor's degree in biological sciences, University of Glasgow, UK

#### Key skills

 Medicine/healthcare/R&D 🖷 Leadership/management 🗠 Finance/accounting Law/regulatory/risk management

## **Corporate Secretary**

Charlotte Pamer-Wieser, Ph.D.

## **Honorary Chairman**

Daniel Vasella, Ph.D.<sup>1</sup>

1 Mr. Vasella does not attend Board meetings and is not provided with Board documents.

## Self-assessment

The Board and its committees conduct a self-assessment once a year, covering topics including Board composition, purpose, scope and responsibilities; succession planning; Board processes and governance; interaction between the Board and the Executive Committee; Board meetings and pre-reading material; team effectiveness; and Board Chair and peer evaluation. Every third year, this process is conducted by an independent external consultant.

The 2023 review was undertaken by the consulting firm Egon Zehnder and its results discussed with the Board of Directors and separately with the Executive Committee during the first half of 2024, where Egon Zehnder shared key observations and recommendations. The results of the 2023 in-depth assessment determined that Novartis has a Board that is performing well and improving, where Directors are highly engaged and have a good rapport, and where there is effective succession and rejuvenation in place. Feedback from management on the Board's evaluation showed that the Executive Committee welcomes the interactions with the Board and its members, as well as the balanced supportive/ challenging dynamics and rich discussions. The report made several recommendations for the Board's consideration, including preparing for the transition to a new Board Chair in 2025 and areas where the Board should focus its attention in the future.

The 2024 self-assessment was conducted internally:

Questionnaire	Review	Outcome
<ul> <li>Each Board member fills out an anonymous survey.</li> <li>A report identifying key strengths and challenges is produced for the Board</li> </ul>	<ul> <li>Based on the results, the Board Chair and the committee chairs each lead a qualitative review with their colleagues and then with the entire Board.</li> </ul>	• The last self-assessment for 2024 determined that the Board and its committees are functioning effectively and efficiently.
and its committees.	<ul> <li>In addition, the Vice-Chair leads a qualitative review of the Board Chair's performance, without the Chair being present, and then provides the Board Chair with the Board's feedback.</li> </ul>	<ul> <li>The feedback confirmed that the Board has an open culture, where different views are encouraged and respected, and that the Board is prepared to adapt and change as circumstances require.</li> </ul>
		• The results also identified key areas on which to focus, such as further development of Novartis strategy, sustained innovation and product pipeline, as well as the impact of the current geopolitical situation including US and China. The evaluation also showed that the Board has a key

## **Trainings**

The Board receives regular briefings and trainings on ethics, risks and compliance, ESG and other relevant topics. In 2024, each Board member completed training on the following:

- The US Healthcare Ecosystem, by Adam Fein
- Adverse event refresher
- Code of Ethics
- · External partner risk management
- · Antitrust / Fair Competition Policy updates
- "Fit to Commit", which focused on anti-bribery, insider trading, conflicts of interest and D&I
- Data ethics and information management, covering key cybersecurity, information management and personal information risks, including AI use

Our Chief Legal Officer also provides regular updates to the Board members on developments related to insider trading laws and regulations and briefs members of the Board and the Executive Committee on an annual basis on their respective duties. In addition, the Company offers a broad range of external training to its Board members.

## **Role of the Board and its committees**

transition.

focus on supporting the Board Chair

The Board is responsible for the overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of decisions reserved for shareholders. Board members are expected to commit the time and effort required to fulfil all their Board and committee responsibilities.

The Board has delegated certain duties and responsibilities to its five committees led by a Board-elected committee chair, as set out in the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In some cases, these responsibilities are of an advisory or preparatory nature. In other cases, the committee has decision-making power that is subject to final Board approval, or the responsibilities have been fully delegated to the committee. All committees have the authority to retain external consultants.

Any Board member may request a Board or committee meeting and the inclusion of an agenda item. Before meetings, Board members receive materials to help them prepare for the discussions and to inform decision-making.

## Attendance at Board and Board Committee Meetings in 2024

Position	Board	Audit and Compliance Committee	Compensation Committee	Governance, Sustainability and Nomination Committee	Risk Committee	Science & Technology Committee
Board Chair	11/11					
Vice-Chair	10/11		6/6			6/6
Lead Independent Director	11/11		6/6	4/4		
Member	9/11				2/4	4/6
Member	10/11	7/7			4/4	
Member	11/11	7/7			4/4	
Member	10/11	7/7	6/6	4/4		
Member	11/11	7/7		4/4		
Member	10/11	7/7				6/6
Member	10/11	7/7			4/4	
Member	10/11			4/4		5/6
Member	11/11		6/6	4/4		
Member	11/11				4/4	6/6
	Board Chair Vice-Chair Lead Independent Director Member Member Member Member Member Member Member Member Member	Board Chair11/11Vice-Chair10/11Lead Independent Director11/11Member9/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11Member10/11	PositionBoardCompliance CommitteeBoard Chair11/11Vice-Chair10/11Lead Independent Director11/11Member9/11Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/11	PositionBoardCompliance CommitteeCompensation CommitteeBoard Chair11/11Vice-Chair10/116/6Lead Independent Director11/116/6Member9/11Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/116/6Member10/116/6Member10/116/6	Audit and Compliance CompensationSustainability and Nomination CommitteeBoard Chair11/11Vice-Chair10/11Ore-Chair10/11Idependent Director11/11Member9/11Member10/117/7Member10/117/7Member10/1111/117/7Member10/1110/117/7Member10/117/7Member10/117/7Member10/117/74/4Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member10/117/7Member11/116/64/4Member11/116/64/4Member11/116/64/4Member11/116/64/4	Audit and Compliance Compliance CommitteeSustainability and Nomination CommitteeSustainability Risk CommitteeBoard Chair11/11Vice-Chair10/1110/116/6Lead Independent Director11/110/116/6Member9/1110/117/7Member10/1111/117/7Member10/1110/117/7Member10/1110/117/76/64/4Member10/1110/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/117/74/4Member10/116/64/4

Further details can be found on pages 115 - 120.

## **Board of Directors**

#### **Primary responsibilities**

- Strategy: decides on the ultimate direction of the Company's business (including portfolio, markets, acquisitions and divestments), considering also key ESG aspects
- · Structure and organization: determines major changes in the Group's structure and organization
- · Culture: oversees the strategy and implementation of the corporate culture
- Ethics and compliance: oversees the Company's ethics and compliance framework, including the approval of fundamental corporate policies such as the Novartis Code of Ethics
- Risk management: oversees the Company's risk management system, the most significant risks, and how these risks are managed
- Finance: determines the Company's accounting system, financial controls and financial planning; and reviews and approves the Annual Report (including the Compensation Report)
- · Non-financial reporting: reviews and approves the Company's annual reporting on non-financial matters
- People and organization: nominates or appoints, removes, and determines responsibilities of key executives, and succession planning

#### Key activities in 2024

- Oversaw the Company's strategy to deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches
- Reviewed the development of the talent pipeline in the context of strengthening the Company's foundations and leadership bench
- Discussed longer-term Board succession planning and required profiles, including the nomination of a new Board Chair and
   a new Board member for election at the 2025 AGM
- Reviewed strategic considerations around mergers and acquisitions (including the acquisition of Mariana Oncology and MorphoSys), and the Company's larger strategic moves to drive sustainable growth
- · Regularly reviewed the Company's overall performance
- · Discussed updates from the US, International and Operations units
- Reviewed the Research Development Commercial Continuum Execution and the priorities of the different Therapeutic areas
- Discussed the Company's ESG strategy, plans and developments, including updates on non-financial disclosure regulations and the non-financial reporting governance of the Company.
- Discussed and reviewed the annual Board self-evaluation including the 2023 in-depth exercise performed by the external firm Egon Zehnder
- · Discussed and assessed the geopolitical situation, with a special focus on the impact of the US election
- Received an update on the Southern Europe, Russia & Central Europe Cluster Business and the Company's strategic
   ambitions and technology platforms in Slovenia

#### Meetings

Number of meetings held	11
Number of members	13
Approximate average duration (hours)	5:35
Meeting attendance	96%

The Board met 10 times in 2024. Regular meetings were held in January, April, June, August, October and December and special meetings called to deal with ad hoc matters. Board committees typically meet the day before the meeting of the full Board. The Board held virtual, hybrid and physical meetings, with participants joining in person whenever possible.

J. Reinhardt (Board Chair)	11
S. Moroney (Vice-Chair)	10
P. Bula (Lead Independent Director)	11
N. Andrews	9
T. Buechner	10
E. Doherty	11
B. Heller	10
D. Hochstrasser	11
F. van Houten	10
A. de Pro Gonzalo	10
C. Sawyers	10
W. Winters	11
J. Young	11

#### **Documents**

- · Articles of Incorporation of Novartis AG
- Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

## **Audit and Compliance Committee**

#### **Primary responsibilities**

- Supervises the external auditor, and selects and nominates the external auditor for election by the shareholders (FD)\*\*
- Oversees Internal Audit (FD)\*\*
- Oversees accounting policies, financial controls, and compliance with accounting and internal control standards (FD)\*\*
- Approves financial statements for the first three quarters of each calendar year and the corresponding financial results releases (FD)\*\*, and reviews the annual financial statements and the corresponding financial results releases (FBA)\*\*\*
- Reviews the non-financial data contained in the Group's annual reporting (FBA)\*\*\*
- · Oversees compliance with laws, regulations and internal policies related to its subject matter expertise (FD)\*\*
- Reviews updates with regards to Quality Assurance and patient safety twice a year and Health Safety & Environment once a year (FD)\*\*
- · Reviews updates from the SpeakUp Office twice a year (FD)\*\*
- · Reviews the Group's tax policy every two years (FD)\*\*
- Reviews updates in closed sessions with the Chief Financial Officer, Chief Audit Officer, and external auditor (FD)\*\*

#### Key activities in 2024

- · Reviewed accounting and financial reporting, focusing on areas involving significant risk or judgment
- Reviewed non-financial reporting
- Received an update on the Company's approach to non-financial reporting and assurance, in joint session with GSNC
- Received an update on the Novartis fraud risk management framework, including the assessment against the Committee of Sponsoring Organizations of the Treadway Commission (COSO) principles
- Liaised with the Risk Committee to ensure adequate oversight of the Company's key transformation projects (Enterprise Data Governance and Management and Lean Digital Core (LDC) program)
- · Monitored progress on the integrated assurance approach
- Evaluated the performance of the external auditor of Novartis, KPMG, during 2024
- Received reports and updates from Internal Audit; Quality; Ethics, Risk & Compliance; the SpeakUp Office; Health, Safety & Environment; and Legal, and discussed progress on identifying and remedying the root causes of any associated issues or problems.

#### **Meetings**

Number of meetings held	7
Number of members	6
Approximate average duration (hours)	2:33
Meeting attendance	100%

E. Doherty (Chair, Audit Committee Financial Expert)	
T. Buechner	7
B. Heller	7
D. Hochstrasser	7
F. van Houten	7
A. de Pro Gonzalo (Audit Committee Financial Expert)	7

### **Documents**

· Board Committees Charter, Appendix I to the Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

\* A/P = advisory or preparatory task

" FD = fully delegated task

" FBA = task subject to final Board approval

## **Compensation Committee**

#### **Primary responsibilities**

- Designs, reviews and recommends compensation policies and programs to the Board (FBA)\*\*\*
- Advises the Board on the compensation of Board members and the CEO (A/P)\*
- Decides on the compensation of Executive Committee members (FD)\*\*
- Prepares the Compensation Report and the Say-on-Pay brochure, and submits them to the Board for approval (FBA)\*\*\*

#### Key activities in 2024

- · Made decisions relating to Executive Committee and wider employee compensation during the year
- Determined the critical performance measures (including financial, strategic, operational, innovation and ESG) to be considered in Executive incentive plan targets
- · Assessed the achievement of incentive plan targets for Executive Committee members
- Reviewed shareholder and proxy advisor feedback related to Novartis compensation practices and disclosures, in addition
  to those of peer companies
- · Reviewed disclosures in the Novartis Compensation Report
- Proposed appropriate peer companies for comparisons of board and executive committee compensation, and assessed the Company's level of compensation against the peer group
- Reviewed incentive plan rules to secure pay-for-performance alignment while preserving market competitiveness
- Reflected on the effectiveness of the Company's compensation programs in view of becoming a pure-play innovative medicines company

#### **Meetings**

Number of meetings held	6	S. Moroney (Chair)	6
Number of members	4	P. Bula	6
Approximate average duration (hours)	1:20	B. Heller	6
Meeting attendance	100%	W. Winters	6

#### **Documents**

· Board Committees Charter, Appendix I to the Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

\* A/P = advisory or preparatory task

- FD = fully delegated task
- " FBA = task subject to final Board approval

## **Governance, Sustainability and Nomination Committee**

#### **Primary responsibilities**

- Oversees the Company's strategy, governance and progress on sustainability, including access to medicines and healthcare, global health, environmental sustainability, human capital management and other material ESG aspects (FBA)\*\*\*
- · Recommends corporate governance best practices to the Board (FBA)\*\*\*
- Reviews the Articles of Incorporation and Board Regulations on a periodic basis (FD)\*\*
- Reviews the composition and size of the Board and its committees as well as the skills matrix on a regular basis (FBA)\*\*\*
- Identifies new Board member candidates and recommends to the Board whether existing Board members should stand for re-election (FBA)\*\*\*
- Prepares and reviews succession plans for the Board Chair, the Vice-Chair, the Lead Independent Director, Board members, committee members and chairs, and the CEO (FBA)\*\*\*
- Reviews the independence of each Board member on an annual basis (FBA)\*\*\*
- Reviews directorships and agreements of Board members for conflicts of interest, and deals with conflicts of interest (FBA)\*\*\*

#### Key activities in 2024

- · Discussed the composition of, and the succession for, the Novartis Board and its committees on a regular basis
- Discussed benchmarking data concerning the board size, composition, diversity, and committee structure of peer
   companies
- Discussed the new Swiss legal requirements on non-financial reporting and the corresponding shareholder vote on the 2023 report on non-financial matters at the 2024 AGM
- · Received an update on the Company's approach to non-financial reporting and assurance, (in joint session with ACC)
- Reviewed an update on ESG Strategy with a focus on trends regarding ESG disclosure regulations and environmental sustainability
- Regularly reviewed updates on the ESG Scorecard to track progress against the sustainability targets for Innovation & Access, Human Capital Management, Environmental Sustainability and Ethical Standards; reviewed the 2025 ESG targets
- Received an update on Novartis Global Health programs and pipeline
- Received an update on human capital management focused on leadership development, our company culture, and
   workforce diversity
- Received an update on environmental sustainability, which covered performance against the targets for climate, water, and waste; the approach to reducing scope 3 emissions (including supplier engagement); and the Novartis strategy on biodiversity
- Reviewed the company's performance to date, upcoming regulations and future Novartis targets on gender balance, equal pay, and pay transparency
- Evaluated the results of the 2024 AGM as well as investor and analyst feedback from ESG and Governance roadshows held during 2024

#### **Meetings**

Number of meetings held	4
Number of members	5
Approximate average duration (hours)	1:31
Meeting attendance	100%

P. Bula (Chair)	4
B. Heller	4
D. Hochstrasser	4
C. Sawyers	4
W. Winters	4

#### **Documents**

· Board Committees Charter, Appendix I to the Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

A/P = advisory or preparatory task

" FD = fully delegated task

···· FBA = task subject to final Board approva

## **Risk Committee**

#### **Primary responsibilities**

- · Oversees the risk management system and processes (FBA)\*\*\*
- · Reviews, together with management, the prioritization and handling of risks, the risk portfolio,
- and actions implemented by management (FBA)\*\*\*
  Performs deep dives into key risk areas and fosters a culture of smart risk-taking (FBA)\*\*\*
- Reviews updates on cyber security on an annual basis (FD)\*\*
- Reviews regular updates from designated risk owners as well as the Chief Ethics, Risk & Compliance Officer and/or the Head of Risk & Resilience (FD)\*\*

#### Key activities in 2024

- · Received updates on Enterprise Risk Management mitigation measures and results
- · Received an update on the artificial intelligence strategy in Biomedical Research and Development organizational units
- Received an update on the falsified medicines risk environment and the progress made in reducing risk for Novartis and its patients
- Discussed the outcome of the Risk Intelligence Forum 2024 and emergency and crisis management
- · Reviewed the pricing reimbursement, access and regulatory process risk update for both the US and International units
- Analyzed opportunities and risks around talent management in key areas, including external workforce and human capital management
- Received updates and closely monitored the strategic technology program implementations, with a special focus on the Lean Digital Core (LDC) program
- Received a deep-dive update on cyber security, including AI and data loss protection
- Evaluated the risks associated with current geopolitical developments (including US election scenarios)
- · Received an update on the Company's supply chain

#### **Meetings**

Number of meetings held	4
Number of members	5
Approximate average duration (hours)	1:51
Meeting attendance	90%

T. Buechner (Chair)	4
N. Andrews	2
E. Doherty	4
A. de Pro Gonzalo	4
J. Young	4

#### **Documents**

· Board Committees Charter, Appendix I to the Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

A/P = advisory or preparatory task

" FD = fully delegated task " FBA = task subject to final Board approval

## Science & Technology Committee

#### **Primary responsibilities**

- Monitors emerging scientific, data-related, technological and research trends and issues, and brings recommendations to the Board (FBA)\*
- Assists the Board with setting the Company's strategy for science, data, technology and research (A/P)\*
- Assists the Board with oversight and evaluation of the performance of the scientific, technological and research teams within the Company in relation to the strategy (FBA)\*\*
- Reviews key portfolio developments by T/A, key research activities, and R&D performance vs. industry benchmarks (A/P)\*
- · Reviews of progress vs. goals for Research & Development. (FD)\*\*
- Reviews other matters in relation to science, data, technology and research that the committee may, at its own discretion, deem desirable in connection with its responsibilities (A/P)\*

#### Key activities in 2024

- · Reviewed the strategy of the Neuroscience Therapeutic Area
- · Discussed the strategy of our Technical Research & Development organizational unit
- · Reviewed the role of the Science & Technology Committee (STC) and approved the updated STC Charter
- · Reviewed the preclinical and early clinical Portfolio Strategy of the Oncology Disease Area
- · Reviewed the preclinical and early clinical Portfolio Strategy of the Cardiovascular Metabolism Disease Area
- · Provided guidance to Merger & Acquisition (M&A) and Business Development & Licensing (BD&L) teams on scientific aspects of key deals
- · Portfolio Updates from Biomedical Research and Development; review of external landscape by Strategy & Growth
- Reviewed R&D performance metrics, including benchmarking, and the Biomedical Research and Development organizational units' plans to enhance performance

#### Meetings

Number of meetings held	6	J. Young (Chair)
Number of members	6	N. Andrews
Approximate average duration (hours)	3:55	F. van Houten
Meeting attendance	92%	S. Moroney
		C. Sawyers

4 6 6

5

#### **Documents**

· Board Committees Charter, Appendix I to the Board Regulations

www.novartis.com/investors/company-overview/corporate-governance

\* A/P = advisory or preparatory task

- \* FD = fully delegated task "FBA = task subject to final Board approval

## **Board Chair**

The Board Chair leads the Board to represent the interests of all stakeholders and ensure an appropriate balance of power between the Board and the Executive Committee. In this role, the Board Chair:

- · Provides leadership to the Board
- · Supports and mentors the CEO
- Ensures that the Board and its committees work effectively
- Sets the agenda, style and tone of Board discussions, promoting constructive dialogue and effective decision-making
- Ensures onboarding programs for new Board members, and continuous education for and specialization of all Board members
- Ensures the Board's annual performance evaluation
- Promotes effective relationships and communication between Board and Executive Committee members
- Ensures effective communication with the Company's shareholders, other stakeholders and the public

## Vice-Chair and Lead Independent Director

#### **Vice-Chair**

The Vice-Chair has the following responsibilities:

- Leads the Board in the event that, and for as long as, the Board Chair is incapacitated
- Leads the yearly session of the Board members to evaluate the performance of the Board Chair, during which the Board Chair is not present

The Vice-Chair also provides advice and support to the Board Chair.

#### Lead Independent Director

To support adequate control mechanisms, the Board Regulations outline the role of the Lead Independent Director. The Lead Independent Director has the following responsibilities:

- · Chairs the sessions of the independent Board members
- Leads the independent Board members in the event of a crisis or matter requiring their separate consideration or decision

The roles of the Vice-Chair and the Lead Independent Director can be held by two Board members or by one Board member (combined role).

The Board appointed Simon Moroney as Vice-Chair and Patrice Bula as Lead Independent Director, both roles effective as of March 4, 2022.

## Mandates outside the Novartis Group

According to article 34, paragraph 1 of the Articles of Incorporation (www.novartis.com/investors/companyoverview/corporate-governance), the following limitations on mandates apply:

	Maximum number of mandates
Mandates	10
Other listed companies <sup>1</sup>	4

<sup>1</sup> Holding a chair position of the board of directors in other listed companies counts as two mandates.

According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/companyoverview/corporate-governance), the following mandates are not subject to the above-mentioned limitations:

Ма	ximum number of mandates
Mandates in companies that are controlled by Novartis AG	No limit
Mandates held at the request of Novartis AG or companies controlled by it	5

"Mandates" shall mean any membership in the board of directors, in the executive board or in the advisory board, or a comparable function under foreign law, in a company with an economic purpose. Mandates in different legal entities that are under joint control are deemed to be one mandate.

For a full list of all external mandates subject to the above-mentioned limitations, please refer to the Compensation Report (see "—Item 6.B Compensation—Mandates outside the Novartis Group").

## **Executive Committee**

## Composition (as per December 31, 2024)

Vasant (Vas) Narasimhan Chief Executive Officer

Shreeram Aradhye President, Development & Chief Medical Officer

Patrick Horber President, International

Fiona H. Marshall President, Biomedical Research Victor Bulto President, US

Harry Kirsch Chief Financial Officer

Klaus Moosmayer Chief Ethics, Risk & Compliance Officer Aharon (Ronny) Gal Chief Strategy & Growth Officer

Robert (Rob) Kowalski Chief People & Organization Officer Karen L. Hale Chief Legal Officer

Steffen Lang President, Operations

## **Role of the Executive Committee**

The Board has appointed the Executive Committee members and delegated overall responsibility for and oversight of the operational management of Novartis to them, including:

- · Recruiting, appointing and promoting senior management
- Ensuring the efficient operation of the Group and the achievement of optimal results
- Promoting an active internal and external communications policy
- Developing policies and strategic plans for Board approval, and implementing those approved
- Submitting the following to the Board for approval: investments, divestments, transactions, contracts and litigations with a value exceeding USD 500 million, and capital market and other important financing transactions, as well as all other matters of fundamental significance to the Novartis Group
- Preparing and submitting quarterly and annual reports to the Board and its committees
- Informing the Board of all matters of fundamental significance to the businesses
- Dealing with any other matters delegated by the Board

There are no contracts between Novartis and third parties whereby Novartis would delegate any business management tasks to such third parties.

## **Chief Executive Officer**

With the support of the Executive Committee, the CEO is responsible for the operational management of Novartis. These responsibilities include effectively implementing the Company strategy, delivering financial results, and shaping a corporate culture of empowerment and responsibility to help drive innovation, performance and reputation.


In addition to other Board-assigned duties, the CEO leads the Executive Committee, and is responsible for building and maintaining an effective executive team. With the support of the Executive Committee, the CEO is responsible for:

- Ensuring Novartis has the capabilities to achieve its long-term strategic objectives
- Developing robust management succession and development plans for presentation to the Board
- Promoting effective communication with shareholders and other stakeholders
- Ensuring Novartis conducts its business in a legal and ethical manner
- Developing an effective risk control framework for all business activities
- Ensuring the flow of information to the Board is accurate, timely and clear

## **Diversity**

The composition of the Executive Committee of Novartis as of December 31, 2024, in terms of nationality, gender, age and length of tenure, is shown in the following charts:

#### **Diversity profile**



Please note that three Executive Committee members have dual nationalities. Each of these nationalities is counted as a half in the above chart.

## Mandates outside the Novartis Group

According to article 34, paragraph 2 of the Articles of Incorporation (www.novartis.com/investors/companyoverview/corporate-governance), the following limitations on mandates apply:

	Maximum number of mandates
Mandates	6
Other listed companies <sup>1</sup>	2

<sup>1</sup> Holding a chair position of the board of directors in other listed companies is not allowed.

According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/companyoverview/corporate-governance), the following mandates are not subject to the above-mentioned limitations:

Ма	ximum number of mandates
Mandates in companies that are controlled by Novartis AG	No limit
Mandates held at the request of Novartis AG or companies controlled by it	5

"Mandates" shall mean any membership in the board of directors, in the executive board or in the advisory board, or a comparable function under foreign law, in a company with an economic purpose. Mandates in different legal entities which are under joint control are deemed one mandate.

For a full list of all external mandates subject to the above-mentioned limitations, please refer to the Compensation Report (see "—Item 6.B Compensation—Mandates outside the Novartis Group").

### **Members of the Executive Committee**



#### Vasant (Vas) Narasimhan, M.D.

Chief Executive Officer since 2018 | Nationality: American | Year of birth: 1976

#### Professional experience

- Global Head of Drug Development and Chief Medical Officer, Novartis AG, Switzerland (2016–2018)
  Global Head of Development, Novartis Pharmaceuticals, Switzerland (2014–2016)
- Global Head of Biopharmaceuticals and Oncology Injectables, Sandoz International, Germany (2014) Global Head of Development, Novartis Vaccines, US (2012–2014)
- · North America Region Head, Novartis Vaccines, and US Country President, Novartis Vaccines and Diagnostics, US (2008-2012)
- Joined Novartis in 2005

#### Mandates Current:

- Member, National Academy of Medicine, US
- Board member, Pharmaceutical Research and Manufacturers of America (PhRMA), US
   Committee member, Biopharmaceutical CEOs Roundtable (BCR), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Switzerland
- Past:
- Chair, Pharmaceutical Research and Manufacturers of America (PhRMA), US (2023-2024)

#### Education

- · Doctor of medicine, Harvard Medical School, US
- Master's degree in public policy, John F. Kennedy School of Government, Harvard University, US
- · Bachelor's degree in biological sciences, University of Chicago, US

#### Shreeram Aradhye, M.D.

President, Development and Chief Medical Officer since May 2022 | Nationality: American | Year of birth: 1962

#### Professional experience

- Executive vice president & chief medical officer, Dicerna Pharmaceuticals, US (2020-March 2022)
- Executive vice president & chief development officer, Axcella Health, US (2019-2020)
- · Global Head, Medical Affairs and Chief Medical Officer, Pharmaceuticals, Novartis, US & Switzerland (2017-2019)
- · Global Head, Development Franchise, Neuroscience, and US Head, Development, Novartis, US & Switzerland (2013-2017)
- Executive Global Program Head, Multiple Sclerosis, Novartis, Switzerland (2012-2013)
- · Head, Global Development India, Novartis, India (2011-2012)
- Head, Global Clinical Development & Medical Affairs, Biosimilars, Sandoz, Germany (2009-2011) · Joined Novartis in 1999 holding positions of increasing responsibility

#### Education

- Chief resident and teaching fellow in internal medicine, Newton Wellesley Hospital, US
   Resident in internal medicine, Newton Wellesley Hospital, US
- · Fellow in nephrology, St Luke's Roosevelt Medical Center, US
- · Resident in internal medicine (M.D.), All India Institute of Medical Sciences, India
- · Bachelor of medicine and bachelor of surgery, All India Institute of Medical Sciences, India



#### Victor Bulto

President, US since April 2022 | Member of the Executive Committee as of May 2022 | Nationality: Spanish | Year of birth: 1978

#### Professional experience

- President, Novartis Pharmaceuticals Corporation, US (2019–April 2022)
- Vice President & Head US Immunology & Dermatology Franchise, US (2017-2019)
- Vice President & Head US Alcon Pharmaceuticals, US (2016-2017)
- · Head Neuroscience Franchise, Region Europe, Novartis, Switzerland (2013-2016)
- Business Franchise Head Neuroscience, Novartis, Spain (2012–2013)
- Business Franchise Head Neuroscience/MS, Respiratory, Osteoarticular, Spain, Novartis (2010–2012)
   Marketing Head Respiratory, Osteoarticular, Novartis, Spain (2009–2010)

#### Mandates

- · Board member, Biotechnology Innovation Organization (BIO), US
- · Board member, Advisory Board of the Leonard D. Schaeffer Center for Health Policy & Economics, US Education

- Master of business administration, ESADE Business School, Spain
- Master's degree in health economics and pharmacoeconomics, Pompeu Fabra University Spain
   Master's degree in chemical engineering, Ramon Llull University, Spain
- · Bachelor's of science degree in chemistry, Ramon Llull University, Spain



#### Aharon (Ronny) Gal, Ph.D.

Chief Strategy & Growth Officer since July 2022 | Nationality: Israeli/American | Year of birth: 1966

#### Professional experience

- Senior analyst, US biopharmaceutical, Sanford Bernstein, US (2020–June 2022)
- Senior analyst, US specialty pharmaceuticals and Biotech, Sanford Bernstein, US (2016-2020)
- Senior analyst, US specialty pharmaceuticals and EU mid-cap pharmaceuticals, Sanford Bernstein, US. UK (2013-2016)
- Senior analyst, US specialty pharmaceuticals, Sanford Bernstein, US (2004-2013)
- Vice president, Canon US Life Sciences, US (2003-2004) Consultant, team leader, manager, The Boston Consulting Group, Inc., US, Singapore, China (1996 - 2002)

#### Education

- Ph.D. in biochemistry, Massachusetts Institute of Technology, US
- B.Sc. in chemistry, Emory University, US

#### Karen L. Hale

Chief Legal Officer since 2021 | Nationality: American | Year of birth: 1968

#### Professional experience

- Vice president, deputy general counsel, AbbVie Inc., US (2019–2021)
  Vice president, chief ethics and compliance officer, AbbVie Inc., US (2013–2019)
- Vice president, litigation and legal specialty operations, AbbVie Inc., US (2013)
- Divisional vice president, commercial litigation, Abbott Laboratories, US (2006-2012)
- Began practicing law in 1994 and joined Abbott in 1997

#### Education

- · Bar memberships: Illinois and Virginia, US
- Juris doctor, William & Mary Law School, US
- · Bachelor's degree in economics, Duke University, US

#### Patrick Horber M.D.

President, International since December 2023 | Nationality: Swiss | Year of birth: 1970

#### Professional experience

- Senior vice president, AbbVie, president Immunology, AbbVie, US (July 2023–September 2023)
  President, US commercial operations, Immunology, AbbVie, US (2020–June 2023)
  Vice president and head of global marketing and commercial operations, AbbVie, US (2019–2020)
- Vice president and managing director, AbbVie, Germany (2015-2019)
- Managing director, AbbVie, Switzerland (2013-2015)
- Managing director, Abbott, Switzerland (2012–2012)
- · Leadership roles at headquarters and country operations, Roche (2005-2012)

#### Mandates Current:

· Member of the board of the European Federation of Pharmaceutical Industries and Associations

#### Past:

- · Member of the board and chair of the strategy and politics committee, Verband Forschender Arzneimittelhersteller, Germany (2016-2019)
- · Interpharma, the association of Switzerland's research-based pharmaceutical industry Chair of the Executive Committee (2015–2015) Member of the President's Bureau (2015–2015)

  - Member of the Executive Committee and the Board (2013-2015)

Chief Financial Officer since 2013 | Nationality: German/Swiss | Year of birth: 1965

### Education

**Harry Kirsch** 

· Doctor of medicine (M.D.), University of Zurich, Switzerland



#### **Professional experience**

- Chief Financial Officer Pharmaceuticals Division, Novartis Pharma AG, Switzerland (2010-2013)
- Chief Financial Officer of Pharma Europe, Novartis Pharma AG, Switzerland (2008-2010)
- Head of Business Planning & Analysis for the Pharmaceuticals Division, Novartis Pharma AG, Switzerland (2005 - 2008)
- Head Finance Global Primary Care, Novartis Pharma AG, Switzerland (2003 2005) · Finance positions at Procter & Gamble (1991 - 2003)

#### Mandates Past:

• Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015-2018)

#### Education

Diploma degree in industrial engineering and economics (Diplom-Wirtschaftsingenieur), University of Karlsruhe, Germany



#### Robert (Rob) Kowalski

Chief People & Organization Officer since September 2021 | Nationality: American | Year of birth: 1968

#### Professional experience

- Executive Vice President and Global Head of Regulatory Affairs (2018-2021), and US Head of Global Drug Development (2009-2015 and 2017-2021), Novartis Pharmaceuticals Corporation, US
- Ad interim President, Novartis Corporation, US (2021)
- · Ad interim Head of Global Drug Development and Chief Medical Officer, Novartis AG,
- Switzerland (2018)
- Senior Vice President and Head of Regulatory Affairs, Novartis Pharmaceuticals Corporation, US (2009-2015 and 2017-2018)
- Senior Vice President and Head of Regulatory Affairs, Novartis Pharma AG, Switzerland (2015–2017)
   Global Head of Country Medical Development, Novartis Pharmaceuticals Corporation, US (2010–2011)
- Previously held regulatory leadership roles at Schering-Plough Corporation (now Merck) and Pharmacia Corporation (now Pfizer)

#### Mandates Past:

• Member of the advisory board, Industry Pharmacists Organization, US (2015 - 2024)

#### Education

- Doctor of pharmacy, University of Wisconsin-Madison, US
- · Bachelor's degree in pharmaceutical sciences, University of Wisconsin-Madison, US

#### Steffen Lang, Ph.D.

President, Operations since April 2022 | Nationality: German/Swiss | Year of birth: 1967

#### Professional experience

- Global Head of Novartis Technical Operations (NTO) (2017–April 2022)
- Global Head of Biologics Technical Development and Manufacturing, Novartis Technical Operations, Switzerland (2015-2017)
- Global Head of Technical Research and Development, Novartis Pharmaceuticals, Switzerland (2009–2015)
  Joined Novartis in 1994 as Head of Laboratory in Research, and over the years held positions of increasing responsibility within Pharmaceuticals Development

#### Mandates

Board member, Bachem Holding AG, Switzerland

#### Education

- Doctorate in pharmaceutical technology, Swiss Federal Institute of Technology, Switzerland
- · Master's degree in pharmaceutical sciences, University of Heidelberg, Germany

#### Fiona H. Marshall, Ph.D.

President, Biomedical Research since November 2022 | Nationality: British | Year of birth: 1964

#### **Professional experience**

- Senior vice president, head of discovery, preclinical and translational medicine, Merck & Co., US, (2021-September 2022)
- Vice president, global head of neuroscience, Merck & Co., US (2019-2021)
- Vice president, head of UK discovery research, Merck & Co., UK (2018-2019)
- Executive vice president and chief scientific officer, Sosei Heptares, UK (2015-2018)
- · Chief scientific officer and founder, Heptares Therapeutics, UK (2006-2018)

#### Mandates

- Member of the Scientific Advisory Board, SciLifeLab, Sweden
- · Fellow, Royal Society, UK Academy of Medical Sciences, and Royal Society of Biology, all UK

#### Education

- · Doctorate in neuroscience, University of Cambridge, UK
- · Bachelor's degree in biochemistry, University of Bath, UK





Klaus Moosmayer, Ph.D.

#### Chief Ethics, Risk & Compliance Officer since 2018 | Nationality: German | Year of birth: 1968

#### Professional experience

- Chief compliance officer, Siemens AG, Germany (2014-2018)
- · Chief counsel compliance, Siemens AG, Germany (2009-2013)
- · Compliance operating officer, Siemens AG, Germany (2007-2009)

#### Mandates

- Current:
- · Board member, SwissHoldings, the Swiss federation representing Swiss-based multinational companies, Switzerland
- Member of the executive board, Business at OECD (BIAC), Paris
- · Co-founder and honorary board member, European Chief Compliance and Integrity Officers' Forum

#### Past:

- Co-Chair, B20 Integrity & Compliance Taskforce under the G20 presidencies of Indonesia (2022), Italy (2021), Saudi Arabia (2020), Argentina (2018), and Chair of the Task Force under the G20 presidency of Germany (2017)
- Chair of the Anti-Corruption Committee of the Business and Industry Advisory Committee (BIAC), Organization for Economic Co-operation and Development (OECD), Paris (2013-2020)

#### Education

- · First and second state examination in law, Germany
- Doctor of jurisprudence, University of Freiburg, Germany

## Information and control systems

The Board's information and control systems vis-à-vis management include a steady flow of information from senior management; monthly financial reports; a comprehensive and integrated risk management framework; and the independent evaluation of our risk management and internal control framework by the Internal Audit function (see "Item 15. Controls and Procedures").

## Information from senior management

The Board ensures that it receives sufficient information from the Executive Committee through:

- Monthly CEO reporting (encompassing progress against company targets, including financial results) and frequent communications from the CEO on current developments
- Executive Committee meeting minutes
- Regular meetings and teleconferences by the Board and/or Board committees with the CEO and/or other members of the Executive Committee (e.g., the CFO, the Chief Legal Officer, the Chief Ethics, Risk & Compliance Officer), and regular meetings and teleconferences with senior management (e.g., the Chief Audit Officer)
- Information from Executive Committee members or other Novartis employees, and visits to Novartis sites

To obtain an outside view, the Board and/or Board committees occasionally invite external advisors (e.g., the independent advisor of the Compensation Committee, the external auditor) to attend a meeting and/or share their observations about a specific topic.

## Monthly financial reports

Novartis produces comprehensive, consolidated (unaudited) financial statements on a monthly basis for the Company. These are typically available no more than 10 days after the end of the month, and include the following:

- Consolidated income statement of the month and year to date, in accordance with IFRS Accounting Standards, as well as adjustments to arrive at core results that are not aligned with IFRS measures, as defined by Novartis (see "Item 5. Operating and Financial Review and Prospects—Item 5.A Operating results—Non-IFRS measures as defined by Novartis"). The IFRS Accounting Standards and core figures that are not aligned with IFRS measures are compared with the prior-year period and targets in both USD and on a constant currency basis.
- Supplementary data on a monthly and year-to-date basis, such as free cash flow and earnings per share on a USD basis

Management information related to the consolidated income statements and free cash flow is made available to Board members through the monthly CEO Report, which includes an analysis of key deviations from the prior year or target.

Prior to the release of each quarter's results, the Board receives the actual consolidated financial statement information and an outlook of the full-year results in accordance with IFRS Accounting Standards and core results that are not aligned with IFRS measures (as defined by Novartis), together with related commentary.

Annually, during the third quarter, the Board approves the Company's strategic plan for the next three years. In the fourth quarter of the year, the Board approves the operating targets for the following year as well as the financial targets for the following three-year period, including a projected consolidated income statement in USD prepared in accordance with IFRS Accounting Standards and non-IFRS measures as defined by Novartis (core results).

The Board does not have direct access to the Novartis financial and management reporting systems but can, at any time, request more detailed information.

## **Risk management**

#### **Overview**

At Novartis, our continued success depends on our ability to manage risk. Our Board has ultimate oversight of the Enterprise Risk Management (ERM) system and regularly reviews the most significant risks and how these are managed. As explained below, the Board is supported by its committees. Furthermore, our Internal Audit function provides an independent evaluation of risk management (see "—Item 6.C Board practices—Information and control systems—Internal Audit").

#### **BOARD COMMITTEES**

#### **RISK COMMITTEE**

- Oversees the risk management system and processes
- Reviews, together with management, the prioritization and handling of risks, the risk portfolio, and actions implemented by management
- Performs deep dives into key risk areas and fosters a culture of smart risk-taking
- Receives updates on cyber security on an annual basis
- Receives regular updates from designated risk owners as well as the Chief Ethics, Risk & Compliance Officer and/or the Head of Corporate Ethics, Risk & Compliance

#### AUDIT AND COMPLIANCE COMMITTEE

- Ensures that Internal Audit plans are aligned with key risks, and that the function provides independent assurance and insights around these risks
- Works closely with the Risk Committee to minimize gaps in risk coverage
- Receives a semiannual presentation from the Chief Ethics, Risk & Compliance Officer
- Receives a quarterly presentation from the Chief Audit Officer on progress achieved in implementing the risk-based audit plan, and key insights about audit and advisory activities
- Pays particular attention to financial risk
- Has closed sessions with the Chief Audit Officer and, upon request, with the Chief Ethics, Risk & Compliance Officer

#### **COMPENSATION COMMITTEE**

 Works closely with the Risk Committee to ensure that the compensation system does not lead to excessive risk-taking (see "-Item 6.B Compensation-Compensation governance-Risk management principles")

#### **EXECUTIVE COMMITTEE OF NOVARTIS**

 Regularly assesses risks and fosters a culture of risk awareness, in line with the Novartis Values and Behaviors and the Novartis Code of Ethics

#### **ETHICS, RISK & COMPLIANCE**

- · Governs the Novartis Code of Ethics
- Provides an integrated ERM framework (which is described in the following section)
- Governs the global compliance program within Novartis
- Administers the Enterprise Policy Management and global Internal Controls framework

## SENIOR LEADERS OF ORGANIZATIONAL UNITS AND GLOBAL FUNCTIONS, AT ALL LEVELS

- Provide appropriate risk management within their area of responsibility
- Establish adequate risk prevention and mitigation strategies when risk exposure is identified, including tracking progress and providing resources for possible actions
- Assess emerging risks, trends and overall exposure as part of the ERM process

#### **Enterprise Risk Management framework**

The Ethics, Risk & Compliance (ERC) function provides an integrated ERM framework to obtain a holistic view of Company risks and drive a culture of smart risk-taking. Under the leadership of the Chief Ethics, Risk & Compliance Officer, the Corporate ERC team is responsible for the overall ERM process which is a fundamental pillar of our Integrated Assurance. This process covers, but is not limited to, risks associated with:

- The research, development, manufacturing, marketing and sales of products
- Finance, taxes, intellectual property, compliance with law and regulations, security, product safety, technology, human resources, and health, safety and environmental protection
- Business objectives and strategies, including mergers and acquisitions
- External factors (e.g. risk amplifiers) such as the social, political and economic environment

The ERM process continued to evolve in 2024. The Corporate ERC team conducted risk workshops and collaborated with all risk assurance and monitoring functions to identify key risks across the Company. Each Novartis unit organized a focused risk workshop including leadership team members. In parallel, risk workshops were held in top countries by revenue and in certain focus markets. Once key risks were identified, mitigation action plans were created to address them in an effective way. The findings from these workshops were consolidated into the Novartis Risk Radar, which enables senior management, the Executive Committee and the Board to focus discussions on key risks and more closely align our corporate strategy with our risk exposure and ways of working.

In 2024, the Corporate ERC team further developed the ERM framework within the Novartis Corporate ERC organization. We developed additional risk management training and launched our risk intelligence forum, an event that brought together internal and external speakers to address emerging trends and threats. We also integrated a critical scope of activities (Trade Sanctions Governance) into the Corporate ERC team. Furthermore, steady progress has been made in our Integrated Assurance journey by creating a holistic control framework linked to enterprise policies, and by further strengthening our Corporate ERC Assurance team by integrating Labor Rights and Data Privacy External Partner Audits to ensure a harmonized and coordinated monitoring process across the Company.

#### SpeakUp Office

Our SpeakUp Office provides a safe place for employees to report potential misconduct, including the option to do so anonymously.

#### **Global Security**

Global Security proactively collects and shares threat intelligence to protect Novartis from situations that may compromise the safety of people, products and assets, and/or the reputation of our organization. Global Security protects patients from counterfeit products and, as part of the SpeakUp process, performs fair and timely investigations into high-risk cases of alleged internal misconduct. It also provides personal security advice and support for Novartis executives and other employees with the utmost discretion.

## **Internal Audit**

#### **Internal Audit Purpose and Function**

The Internal Audit function supports the Board and Executive Committee by providing independent assurance. It evaluates the effectiveness, efficiency, and adequacy of processes and controls, ensuring that Novartis meets its strategic objectives, manages major risks, and complies with applicable policies, laws, and regulations.

The Chief Audit Officer (CAO) reports administratively to the CEO and functionally to the Chair of the Audit and Compliance Committee (ACC). The CAO meets with the ACC at least quarterly and annually reaffirms the organizational independence of the Internal Audit function to the ACC.

In 2024, Internal Audit executed a risk-based audit plan, with results reported to audited units, the Executive Committee, and the ACC. Audit findings and action plans are centralized to ensure efficient follow-up. To the right is a summary of the audits and advisory activities conducted in 2024, along with key methodology steps for managing the Internal Audit cycle.

#### **2024 INTERNAL AUDIT ACTIVITIES**

# audits



## Internal Audit cycle methodology includes:

- Discovery (planning): Ongoing monitoring and information gathering through continuous risk assessments, utilizing business interviews, and biannual calibration of the audit plan. The plan is reviewed and approved by the Audit Committee (ACC) every six months.
- Execution and Reporting: 37 engagements delivered in 2024, all linked to group risks, emerging topics and company-wide initiatives.
- Follow Up: Management is responsible for resolving issues, supported by Internal Audit to ensure timely closure of high-risk observations.

Internal Audit performed 95% of planned activities (equating to 76 of 80 engagements) in 2024.

## **Auditors**

## Duration of the mandate and terms of office

On behalf of the Board, the ACC selects and nominates an independent auditor for election at the AGM. KPMG commenced its auditing mandate for Novartis in 2022. Richard Broadbelt, Auditor in charge, and Heidi Broom-Hirst, Global Audit Partner, began serving in their roles in 2022 and 2023, respectively. The ACC together with KPMG will ensure that these partners are rotated at least every five years.

## Auditing fees and additional fees

The ACC monitors and preapproves the fees paid to the external auditor for all audit and non-audit services. It has developed and approved a policy with clear guidelines on the engagement of the independent auditor firm. This policy is designed to help ensure that the independence of the external auditor is maintained. It limits the scope of services that the external auditor may provide to the Company, stipulating certain permissible types of audit-related and non-audit services, including tax services and other services that have been preapproved by the ACC. The ACC preapproves all other services on a case-by-case basis.

The external auditor is required to report periodically to the ACC about the scope of the services it has provided to the Company and the fees for the services it has performed to date. KPMG fees for professional services related to the 12-month periods ended December 31, 2024, and December 31, 2023, are as follows:

	2024 USD million	2023 USD million
Audit services	25.3	26.8
Audit-related services	1.9	2.5
Tax services	0.1	0.3
Other services	0.0	0.0
Total	27.3	29.6

Audit services include work performed to issue opinions on consolidated financial statements and parent company financial statements of Novartis AG, to issue opinions related to the effectiveness of the Company's internal control over financial reporting, and to issue reports on local statutory financial statements. Also included are audit services that can generally only be provided by the statutory auditor, such as the audits of the Compensation Report, special purpose financial statement in connection with divestment transactions, information systems and the related control environment; and reviews of quarterly financial results. Audit-related services include other assurance services provided by the independent auditor but not restricted to those that can only be provided by the statutory auditor. They include services such as: limited assurance on selected sustainability information in the Novartis in Society Integrated Report, audits of pension and other employee benefit plans; audit services in connection with non-recurring transactions; assurance of the Compensation Report of Novartis; and other audit-related services.

Tax services include tax compliance and assistance with historical tax matters.

Other services include license fees for use of accounting and other reporting guidance databases and, in 2024, additionally procedures related to training on emerging topics and benchmarking studies.

## Information to the Board and the ACC

The ACC, acting on behalf of the Board, is responsible for overseeing the activities of the external auditor. In 2024, this committee held seven meetings. KPMG was invited to all of these meetings to attend the discussions on auditing matters and any other matters relevant to its audit.

The ACC recommended to the Board to approve the audited consolidated financial statements and the separate parent company financial statements of Novartis AG for the year ended December 31, 2024. The Board proposed the acceptance of these financial statements for approval by the shareholders at the next AGM.

The ACC regularly evaluates the performance of the external auditor and, based on this, once a year determines whether the external auditor should be proposed to the shareholders for re-election. To assess the performance of the external auditor, the ACC requests input from management and holds private meetings with the CFO and the Chief Audit Officer and, if necessary, obtains an independent external assessment. Criteria applied for the performance assessment of the external auditor include an evaluation of: its technical and operational competence; its independence and objectivity; the sufficiency of the resources it has employed; its focus on areas of significant risk to Novartis; its willingness to probe and challenge; its ability to provide effective, practical recommendations; and the openness and effectiveness of its communications and coordination with the ACC, the Internal Audit function and management.

Once a year, the Auditor in charge and the Global Audit Partner report to the Board on the external auditor's activities during the current year, and on the audit plan for the coming year.

On an annual basis, the external auditor provides the ACC with written disclosures required by the US Public Company Accounting Oversight Board, and the committee and the external auditor discuss the external auditor's independence from Novartis.

## **Information policy**

Novartis is committed to open and transparent communication with shareholders, investors, financial analysts, customers, suppliers and other stakeholders. Novartis disseminates information about material developments in its businesses in a broad and timely manner that complies with the rules of the SIX Swiss Exchange and the NYSE.

## Communications

Novartis publishes this Annual Report to provide information on the Group's results and operations. Novartis discloses financial results in accordance with IFRS Accounting Standards on a quarterly basis, and issues press releases from time to time regarding business developments.

Novartis publishes press releases related to financial results and material events to the US Securities and Exchange Commission (SEC) via Form 6-K. An archive containing annual reports, US SEC Form 20-F, quarterly results releases and all related materials – including presentations and conference call webcasts – is available at www.novartis.com/investors.

Novartis also publishes the Novartis in Society Integrated Report, available at www.novartis.com/reportinghub, which provides an overview of our business, strategy and performance, and describes how we create value for stakeholders and society. The Novartis in Society Integrated Report is prepared in accordance with Art. 964b of the Swiss Code of Obligations, and in alignment with recommendations and standards issued by the Integrated Reporting Framework, the Sustainability Accounting Standards Board (SASB), and the Global Reporting Initiative (GRI).

The information on Board and Executive Committee compensation is outlined in the Compensation Report

(see "-Item 6.B Compensation" in general, and for certain compensation information with respect to our Board that is responsive to Item 6.C.2 of Form 20-F, see "-Item 6.B Compensation-Board compensation philosophy and fee structure-Philosophy and benchmarking"). Please also refer to articles 29-35 of the Articles of Incorporation (www.novartis.com/investors/company-overview/ corporate-governance). No change-of-control or 'golden parachute' clauses benefit Board members, Executive Committee members, or other members of senior management. Employment contracts with Executive Committee members are either for a fixed term not exceeding one year or for an indefinite period with a notice period not exceeding 12 months, and do not contain commissions for the acquisition or transfer of enterprises or severance payments. No loans or credits are granted to Board and Executive Committee members.

Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.

## **Investor Relations**

Investor Relations manages the Company's interactions with the international financial community. Several events are held each year to provide institutional investors and analysts with various opportunities to learn more about Novartis.

Investor Relations is based at the Company's headquarters in Basel. Part of the team is located in the US to coordinate interaction with US investors. More information is available at www.novartis.com/investors.

Торіс	Information	
Share capital	Articles of Incorporation of Novartis AG https://www.novartis.com/sites/novartiscom/files/statuten-en.pdf Novartis key share data www.novartis.com/investors/share-data-analysis	
Shareholder rights	Articles of Incorporation of Novartis AG www.novartis.com/investors/company-overview/corporate-governance	
Annual General Meeting of Shareholders	Annual General Meeting of Shareholders www.novartis.com/investors/shareholder-information/annual-general-meeting	
Board Regulations	Board Regulations www.novartis.com/investors/company-overview/corporate-governance	
Novartis code for senior financial officers	Novartis Code of Ethical Conduct for CEO, ECN and Senior Financial Officers of Novartis www.novartis.com/investors/company-overview/corporate-governance	
Novartis in Society Integrated Report	Novartis in Society Integrated Report www.novartis.com/reportinghub	
Novartis Annual Report and Form 20-F	Novartis Annual Report and Form 20-F www.novartis.com/reportinghub	
Novartis Financial Data	Novartis Financial Data www.novartis.com/investors/financial-data	
Press releases	Press releases www.novartis.com/news/news-archive?type=media_release Email service www.novartis.com/news/stay-up-to-date	
Additional information (including event calendar, registered office, contact and email addresses, phone numbers, etc.)	Novartis Investor Relations www.novartis.com/investors	

### Website information

The information on our website is not, and shall not be deemed to be, a part of this Annual Report or incorporated herein.

## **Quiet periods**

According to our Global Insider Policy, employees who have access to material non-public information on a regular basis are designated as Continuing Insiders and are banned from trading in Novartis securities during quiet periods. Limited exemptions for the expiry of options or warrants within a quiet period apply. Our quarterly quiet periods commence on the first trading day of each calendar quarter and end at the beginning of the first trading day after the subsequent release of the quarterly and/or annual results.

In 2024, the following quiet periods applied:

- January 1, 2024 until (and including) January 31, 2024
- April 1, 2024 until (and including) April 23, 2024
- July 1, 2024 until (and including) July 18, 2024
- October 1, 2024 (and including) October 29, 2024